Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | MMP13 | P45452 | 3/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | USP2 | O75604 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8245692 | 1.00 | ALDH1A1 (0.68) | ALDH1A1MMP13HTTSMN1; SMN2HPGD | |
| SCHEMBL8642114 | 0.91 | ALDH1A1 (0.58) | ALDH1A1MMP13HTTSMN1; SMN2HPGD | |
| SCHEMBL4461230 | 0.88 | ALDH1A1 (0.65) | ALDH1A1MMP13HTTSMN1; SMN2HPGD | |
| SCHEMBL3815151 | 0.87 | ALDH1A1 (0.72) | ALDH1A1MMP13HTTSMN1; SMN2HPGD | |
| SCHEMBL17397649 | 0.86 | EPHX2 (0.79) | ALDH1A1HTTSMN1; SMN2HPGDPOLB | |
| SCHEMBL2931410 | 0.85 | MMP13 (0.70) | ALDH1A1MMP13HTTSMN1; SMN2HPGD | |
| SCHEMBL660541 | 0.85 | MMP13 (0.70) | ALDH1A1MMP13HTTSMN1; SMN2HPGD | |
| SCHEMBL23771131 | 0.84 | ALDH1A1 (0.65) | ALDH1A1MMP13HTTSMN1; SMN2HPGD | |
| SCHEMBL21254127 | 0.84 | ALDH1A1 (0.74) | ALDH1A1MMP13HTTSMN1; SMN2HPGD | |
| SCHEMBL875811 | 0.84 | MTNR1A (0.63) | ALDH1A1HTTSMN1; SMN2POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025061176-A1 | CYCLOALKANE-SUBSTITUTED AMINE DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海科技大学 | 2025-03-27 | — | — | WO | disclosed |
| CN-119661404-A | Cycloalkane substituted amine derivative, preparation method and application thereof | 上海科技大学 | 2025-03-21 | — | — | CN | disclosed |
| US-20240092745-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2024-03-21 | — | — | US | disclosed |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | PDE6C, PDE6A, PDE6D | ALDH1A1 1084/4885MMP13 782/4885HTT 913/4885 |
| US-20240092745-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PDE6C, PDE6A, PDE6D | ALDH1A1 1084/4885MMP13 782/4885HTT 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.